



ADULT MEDICATION GUIDELINE

Argipressin (Vasopressin)

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the **Disclaimer**.

Quick Links

DoseAdministrationMonitoringPregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

SAS Category A (item requires approval by TGA)

Medication Class

Antidiuretic hormone

Presentation

Ampoule: 1mg/mL (equivalent to 20units/mL)

Storage

SAS stock: Store at room temperature, below 25°C

Dose

Refer to Clinical Guideline: Gynaecology (Non-oncological)

Administration

Refer to Clinical Guideline: Gynaecology (Non-oncological)

Monitoring

Extravasation may cause tissue necrosis

May cause hyponatraemia with water retention

Pregnancy

1st Trimester: Consider alternative.
2nd Trimester: Consider alternative.
3rd Trimester: Consider alternative.

Breastfeeding

Considered safe to use.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Gynaecology (Non-oncological)

References

Australian Medicines Handbook. Vasopressin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Nov 10]. Available from: https://amhonline.amh.net.au/

Society of Hospital Pharmacists of Australia. Vasopressin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Nov 10]. Available from: http://aidh.hcn.com.au

The Royal Women's Hospital. Vasopressin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Nov 9]. Available from: https://thewomenspbmg.org.au/

Keywords	Argipressin, vasopressin, ADH, antidiuretic hormone, vasoconstrictor, pitressin					
Document Owner:	Chief Pharmacist					
Author/ Reviewer	KEMH Pharmacy Department					
Version Info:	4.0					
Date First Issued:	July 2015	Last Reviewed:	Nov 2021		Review Date:	Dec 2024
Endorsed by:	Medicines and Therapeutics Committee				Date:	Jan 2022
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care		
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety		
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management		
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled.						
Access the current version from WNHS HealthPoint.						

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.